Abstract 140P
Background
Colorectal adenomas (AA) are pre-cursors for 85% of the cancers. Methylation and copy-number alterations are well described in colorectal cancer (CRC) context. We aimed to investigate these signals on AA sub-types.
Methods
Whole-genome Enzymatic Sequencing was performed on advanced adenoma (AA) and adjacent control (CNT) tissues of serrated (14), tubular (26), tubulovillous (24) and villous (10) patient samples, alongside colorectal cancer (CRC) stage I samples (23). Differential methylation analysis pipeline was applied, first to identify regions that are significantly altered between all AA subgroups and CNT tissue and then further investigated for sub-type and CRC I level differences. Additionally, mutation and copy-number alteration (CNA) detection were performed, alongside pathway enrichment.
Results
Initial differential methylation analysis revealed 7725 regions significantly altered between AA and CNT tissue. 137 and 2093 and 91 of those were hypermethylated between serrated vs tubular, serrated vs tubulovillous, tubular vs tubulovillous sub-types respectively. Main pathways, differentiating serrated adenomas from the rest, belong to cAMP signalling, regulation of pluripotency of stem cells, while regions separating tubular and tubulovillous were enriched for WNT signalling. These differential signals could not be seen in stage I CRC samples, which presented CNT-like methylation. The CNA signals were mostly present in tubular or tubulovillous samples. The most frequent signals could be seen in chr7, 12, 19 and 20. Majority of CRC I exhibited CNA in chr 7, 8 and 20, indicating difference processes to be in place between AA and CRC I progression. Differences could also be observed on sub-type level, when looking at tumour mutational burden and specific mutations in APC and KRAS genes.
Conclusions
Colorectal adenoma histological subtypes show distinctly different methylation, CNA and mutational signals, between groups and compared CRC I. These findings are especially important when developing early detection or cancer prevention tests trying to capture adenoma (sub-type level) signatures. These results have been followed by plasma-based biomarker detection studies for pre-cancer screening intent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universal Diagnostics S.A.
Funding
Universal Diagnostics S.A.
Disclosure
F.M. Mancuso, P. Canal Noguer, K. Kruusmaa: Financial Interests, Personal, Full or part-time Employment: Universal Diagnostics.
Resources from the same session
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01